Alagille syndrome (ALGS) is a multi-system autosomal dominant disorder that often presents with neonatal cholestasis.  First described over 50 years ago by Daniel Alagille, this complex syndrome is caused by mutations in JAG1 or NOTCH2, encoding components of the Notch signaling pathway.  Ongoing research has led to a number of important recent advances in our understanding of ALGS.  Specifically, this webinar will focus on the state-of-the-art in genomic diagnostics (presented by Drs. Nancy Spinner and Melissa Gilbert), multi-center studies of disease outcome (presented by Dr. Binita Kamath) and new therapeutic options (presented by Dr. Saul Karpen).  The moderator, Dr. Kathleen Loomes, will summarize how our knowledge of the genetics and pathophysiology of ALGS might lead to new therapies.